Beijing Med-Pharm Corporation Raises $6.3 Million in Private Placement.

PLYMOUTH MEETING, Pa. -- Beijing Med-Pharm Corporation (BJGP.PK) today announced that it has completed a private placement of 4,199,981 shares of its common stock to a group of institutional and individual accredited investors, for gross proceeds to Beijing Med-Pharm of $6,300,000. The investors also received five-year warrants to purchase an aggregate of 1,049,828 shares of common stock, half of which have an exercise price equal to $1.875 and the balance of which have an exercise price equal to $2.25. Beijing Med-Pharm expects to use the proceeds from the private placement to further expand its business in China and for additional working capital. Philadelphia Brokerage Corporation acted as placement agent.

"The strong investor interest we have seen underscores the progress we've made as we build upon our model," says Martyn D. Greenacre, Chairman of Beijing Med-Pharm. "These additional funds will enable Beijing Med-Pharm to expand upon our acquisition and licensing strategy throughout China."

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were sold in a private placement pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Company has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors and shares of common stock issuable upon exercise of the warrants acquired by the investors.

About Beijing Med-Pharm

Beijing Med-Pharm Corporation is a pharmaceutical marketing company that offers the following services in China through its wholly-owned subsidiary, Beijing Med-Pharm Market Calculating Co. Ltd.: pre-market entry analysis; clinical trial management; product registration; market research; and pharmaceutical marketing to physicians, hospitals and other healthcare providers.

For more information, contact Ben Austin at [phone].

On the Web: http://www.beijingmedpharm.com

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995 regarding Beijing Med-Pharm's use of proceeds from the private placement and its expansion plan. Forward-looking statements provide Beijing Med-Pharm's current expectations or forecasts of future events. Beijing Med-Pharm's use of proceeds and expansion plan may differ materially from those reflected in these forward-looking statements due to Beijing Med-Pharm's business opportunities and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, and due to risks and uncertainties associated with these conditions, including those set forth in Beijing Med-Pharm's filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, these forward-looking statements may prove to be incorrect. Therefore, you should not rely on these forward-looking statements. Beijing Med-Pharm undertakes no obligation to update publicly any forward-looking statement.